Daiichi Sankyo Company

Daiichi Sankyo Company is a Japanese pharmaceutical company, one of the world's top 20 companies by sales volume. It owns the U.S. biotechnology company Plexxikon and the German biotechnology company U3 Pharma. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Daiichi Sankyo Company stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Daiichi Sankyo Company balance sheet

Report period2018 2019 2020 2021 2022Q1 23
End date of the reporting period
Capitalization, JP¥
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Daiichi Sankyo Company cash flows

Report period2018 2019 2020 2021 2022Q1 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Daiichi Sankyo Company multipliers

Report period2018 2019 2020 2021 2022Q1 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Daiichi Sankyo Company profitability

Report period2018 2019 2020 2021 2022Q1 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Daiichi Sankyo Company assets
Daiichi Sankyo Company cash flows
Daiichi Sankyo Company dividends
0%

Daiichi Sankyo Company dividend policy

The сompany provides dividends every half year

Daiichi Sankyo Company shares

TickerNameTypeNominal valueISINPrice
DSNKY:USDaiichi Sankyo CompanyDepositary receipt-US23381D1028$32.6
Daiichi Sankyo Company news
27.04.2022
Daiichi Sankyo's IFRS net profit for 2021 was JP¥73.516 billion, down 0.8% from JP¥74.124 billion in the previous year. Revenue rose 8.5% to JP¥1.045 trillion from JP¥0.963 trillion a year earlier.
Source: {source} pictogram daiichisankyo.com
Pictogram next
31.01.2022
Daiichi Sankyo's IFRS net income for 9M FY2021 was JP¥94.318 billion, up 24.4% from JP¥75.806 billion in the previous year. Revenue rose 9.8% to JP¥810.967 billion from JP¥738.791 billion a year earlier.
Source: {source} pictogram daiichisankyo.com
Pictogram next
29.10.2021
Daiichi Sankyo Company's IFRS net profit for 6M FY2021 was JP¥62.465 billion, up 21.1% from JP¥51.594 billion in the previous year. Revenue rose 10.4% to JP¥529.965 billion from JP¥480.168 billion a year earlier.
Source: {source} pictogram daiichisankyo.com
Pictogram next
All Daiichi Sankyo Company news
General information
Company nameDaiichi Sankyo Company
Tags#pharmacy, #biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address3-5-1, Nihonbashi-honcho Chuo-ku Tokyo 103-8426 Japan
Mailing address3-5-1, Nihonbashi-honcho Chuo-ku Tokyo 103-8426 Japan
Websitewww.daiichisankyo.com